Therapeutic Area | MeSH |
---|---|
infections | D007239 |
stomatognathic diseases | D009057 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NOXAFIL | Merck & Co | N-205596 RX | 2014-03-13 | 1 products, RLD, RS |
NOXAFIL POWDERMIX KIT | Merck & Co | N-214770 RX | 2021-05-31 | 1 products, RLD, RS |
NOXAFIL | Merck & Co | N-022003 RX | 2006-09-15 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
noxafil | New Drug Application | 2024-10-25 |
posaconazole | ANDA | 2025-06-27 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
mycoses | — | D009181 | B35-B49 |
oral candidiasis | EFO_0007406 | D002180 | B37.0 |
Expiration | Code | ||
---|---|---|---|
POSACONAZOLE, NOXAFIL, MERCK SHARP DOHME | |||
2028-06-17 | ODE-355 | ||
2024-06-17 | I-881 | ||
2024-05-31 | NPP | ||
POSACONAZOLE, NOXAFIL POWDERMIX KIT, MSD MERCK CO | |||
2024-05-31 | NP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Mycoses | D009181 | — | B35-B49 | 5 | 6 | 7 | 4 | 6 | 28 |
Invasive fungal infections | D000072742 | — | — | 4 | 2 | 4 | 2 | 4 | 16 |
Infections | D007239 | EFO_0000544 | — | 4 | 3 | 2 | 4 | 2 | 15 |
Communicable diseases | D003141 | — | — | 4 | 1 | 1 | 2 | 2 | 10 |
Aspergillosis | D001228 | EFO_0007157 | B44 | — | 1 | 2 | 2 | 1 | 6 |
Invasive pulmonary aspergillosis | D055744 | — | B44.0 | — | 1 | 1 | 1 | — | 3 |
Candidiasis | D002177 | — | B37 | — | 1 | 1 | 1 | — | 3 |
Neutropenia | D009503 | — | D70 | 1 | — | 1 | 1 | — | 3 |
Myeloid leukemia acute | D015470 | — | C92.0 | — | — | 1 | 1 | — | 2 |
Myeloid leukemia | D007951 | — | C92 | — | — | 1 | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | 1 | — | — | 2 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 1 | — | — | 2 |
Oral candidiasis | D002180 | EFO_0007406 | B37.0 | — | 1 | 1 | — | — | 2 |
Pulmonary aspergillosis | D055732 | EFO_1001834 | — | — | — | 1 | — | — | 1 |
Leukopenia | D007970 | EFO_0004233 | D72.819 | — | — | 1 | — | — | 1 |
Coccidioidomycosis | D003047 | EFO_0007211 | B38 | — | — | 1 | — | — | 1 |
Coccidiosis | D003048 | EFO_0007212 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | — | — | — | 1 |
Aplastic anemia | D000741 | — | D61.9 | — | 1 | — | — | — | 1 |
Preleukemia | D011289 | — | — | — | 1 | — | — | — | 1 |
Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
Chagas disease | D014355 | EFO_0008559 | B57 | — | 1 | — | — | — | 1 |
Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
Onychomycosis | D014009 | — | B35.1 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lung transplantation | D016040 | — | — | — | — | — | — | 1 | 1 |
Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Respiratory tract infections | D012141 | — | J06.9 | — | — | — | — | 1 | 1 |
Drug common name | Posaconazole |
INN | posaconazole |
Description | Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication.
|
Classification | Small molecule |
Drug class | systemic antifungals (miconazole type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O |
PDB | — |
CAS-ID | 171228-49-2 |
RxCUI | — |
ChEMBL ID | CHEMBL1397 |
ChEBI ID | 64355 |
PubChem CID | 147912 |
DrugBank | DB01263 |
UNII ID | 6TK1G07BHZ (ChemIDplus, GSRS) |